CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Comera Life Sciences Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Comera Life Sciences Holdings Inc
12 Gill Street, Suite 4650
Phone: (617) 871-2101p:617 871-2101 WOBURN, MA  01801  United States Ticker: CMRACMRA
Business Summary
Comera Life Sciences Holdings, Inc. is a pre-clinical biotechnology company. The Company applies a knowledge of formulation science and technology to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The Company is engaged in developing an internal portfolio of therapeutic product candidates using its proprietary formulation platform, SQore. Its proprietary formulation platform, SQore, is designed to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. Its product programs include CLS-001, a preclinical stage bio better for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage bio better for various oncology indications. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to its partners’ biologic medicines to deliver enhanced SQ formulations.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes-Yes-

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Chief Financial Officer Michael G.Campbell 55 1/31/2024 4/1/2022
Chief Business Officer Janice M.Mccourt 61 11/1/2022 11/1/2022
Independent Director RoopomBanerjee 46 9/1/2021 9/1/2021
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
OTR Acquisition Corp. 1395 Brickell Avenue Miami FL United States

Business Names
Business Name
CMRA
Comera Life Sciences, Inc.
OTR Acquisition Corp.
OTRA
OTRAU

General Information
Number of Employees: 12 (As of 12/31/2022)
Outstanding Shares: 30,737,796 (As of 11/8/2023)
Shareholders: 67
Stock Exchange: OTC
Federal Tax Id: 852136914
Fax Number: (561) 694-1639


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024